Meeting
2013 ASCO Annual Meeting
A phase I dose-escalation study of volasertib (BI 6727) combined with nintedanib (BIBF 1120) in advanced solid tumors.
Authors
Filippo G. De Braud
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Filippo G. De Braud , Stefano Cascinu , Gianluca Spitaleri , Korinna Pilz , Laura Clementi , Dan Liu , Patricia Glomb , Tommaso De Pas
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics
Sub Track
Cytotoxic and Other Novel Agents
Clinical Trial Registration Number
NCT01022853
Citation
J Clin Oncol 31, 2013 (suppl; abstr 2556)
DOI
10.1200/jco.2013.31.15_suppl.2556
Abstract #
2556
Poster Bd #
3H
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Preliminary efficacy from an ongoing phase 1 dose escalation study of seclidemstat (SP-2577) in patients (pts) with advanced solid tumors (AST).
First Author: Sant P. Chawla
Poster
2019 ASCO Annual Meeting
Phase I study of the Aurora A kinase (AurA) inhibitor TAS-119 with paclitaxel (P) in advanced solid tumors.
First Author: Dana Backlund Cardin
Poster
2015 ASCO Annual Meeting
First-in-man combination phase I study of TAS-114 and S-1 in patients (pts) with advanced solid tumors.
First Author: Toshihiko Doi
Poster
2015 ASCO Annual Meeting
Phase I study of receptor tyrosine kinase (RTK) inhibitor, MGCD265, in patients (pts) with advanced solid tumors.
First Author: Christian K. Kollmannsberger